Remission Through Early Monitored Insulin Therapy - Duration Month: Complete Statistical Analysis

1. Trial at a Glance

This page covers the registry results for Remission Through Early Monitored Insulin Therapy - Duration Month (NCT03670641), a na phase 4 study. The primary outcome is Change in Baseline A1C and A1C Measured at 3 Month Intervals up to 12 Months.

2. Clinical Question

3. Trial Design

This completed study is registered as a Phase 4, single-group feasibility pilot with enrollment of 10. It concerns early monitored insulin therapy for people with newly diagnosed type 2 diabetes. The registry describes the intervention as basal glargine and bolus lispro, titrated using glucose levels and trends from a Dexcom G6 continuous glucose monitor. Treatment was intended to continue for up to 4 weeks, with insulin stopped after that period.

The design has no separate comparison group. Allocation is recorded as NA, and masking is listed as NONE. Those features mean the registry does not describe random assignment between intervention and control groups or blinded assessment. The primary measurements are repeated A1C values: baseline and follow-up at 3-month intervals up to 12 months. This structure can describe how measurements change over time among participants, but without a control group it cannot separate changes associated with the intervention from other influences over time.

The stated rationale is feasibility and exploration of remission after early insulin therapy. Secondary outcomes include participants with A1C of <6.5% after the intervention, participants with glucose values <55 mg/dL during the 4-week intervention, diabetes distress assessed with the Problem Areas In Diabetes (PAID) - 5 Questionnaire Scale, time glucose remains in range while wearing the monitor, and participants achieving euglycemic glucose targets within a 4-week period. The registry lists 6 outcome measures, but no analysis results are reported. Further details about recruitment procedures, protocol deviations, and the statistical analysis plan are not reported in the registry record.

4. Participant Flow and Accounting

The registry reports how participants moved through each stage of the study. All counts below are exactly as posted; missing counts are not inferred from other stages.

Overall Study

Reasons for not completing this period:

Analysis population for the primary outcome, as defined in the registry: Individuals recruited had newly diagnosed type 2 diabetes, never on insulin therapy. They may have been on other anti-hyperglycemic agents. The reason why the number analyzed in one or more rows differs from the overall number analyzed is because two of the patients unfortunately did not get baseline A1C measurements. and starting at month 6, 3 participants were lost to follow up

5. Baseline Characteristics

The table reproduces the baseline characteristics posted in the registry, which describe the participants analysed at baseline and help show whether the randomized groups were comparable.

6. Primary Endpoint

The registry lists the primary outcome as Change in Baseline A1C and A1C Measured at 3 Month Intervals up to 12 Months, measured over Every 3 months up to 1 year.

The primary endpoint is described as change in baseline A1C and A1C measured at 3-month intervals up to 12 months. A1C is reported as a percentage of glycosylated hemoglobin, with the outcome parameter specified as a mean and dispersion specified as standard deviation. The planned measurement schedule begins at baseline and continues at regular follow-up intervals. The registry description says the purpose is to assess whether the aggregate A1C value improves after insulin and CGM-guided titration.

As general context, A1C is used to summarize glycemia over time rather than capture a single glucose reading. Repeated measurement can show whether a participant's A1C changes across follow-up and whether the pattern appears sustained. A mean describes the central value across the analyzed participants; a standard deviation describes the spread of individual values around that mean. Neither statistic alone reveals how much uncertainty surrounds the estimated mean or change. A confidence interval would provide information about that uncertainty, but no confidence interval or endpoint estimate is reported in the registry record.

The record does not define a single follow-up visit as the primary comparison, nor does it report a statistical contrast, an analysis population, or an A1C result. The endpoint's measurement schedule and intended purpose are described, but the available record does not establish the magnitude, direction, or precision of any observed change.

7. Why No Re-analysis Is Shown

8. Statistical Interpretation

9. Statistical Methods Explained

The registry describes a continuous primary outcome summarized as a mean with standard deviation. It does not report an analysis result, a confidence interval, a p-value, or a detailed analysis plan. The statistical ideas below are general explanations of how such measures are commonly interpreted, not claims about analyses performed in this study.

What does a mean describe?

For a continuous measure such as A1C, the mean is a central summary across the observations included in an analysis. The interpretation depends on which participants and visits are included. In a repeated-measure setting, a mean at baseline and a mean at a later visit may describe the group at each time point. A mean change instead summarizes individual or group-level differences between specified measurements. These summaries are not interchangeable. The registry record names change in baseline A1C and repeated follow-up measurements, but does not give a precise contrast or the actual values.

A group mean can also hide variation between people. Two groups or visits can have similar means while differing in the spread or shape of individual measurements. Conversely, a mean can change while some participants' values move in different directions. The record specifies standard deviation as the dispersion measure, but does not report a standard deviation. Without the underlying distribution or summary results, the pattern among individual participants cannot be assessed.

How should standard deviation be read?

In general, standard deviation describes how spread out observations are around their mean. It is a measure of variability among observations, not a direct measure of uncertainty in the mean. A larger standard deviation indicates more dispersed values in the analyzed group; it does not by itself show whether a mean is estimated precisely. Precision also depends on how many observations contribute and on the analysis design. The registry gives an overall enrollment of 10, but it does not report visit-specific analysis counts or standard deviations.

Repeated measurements on the same participant are related rather than independent. General methods for longitudinal data account for this within-person relationship when estimating changes or testing patterns over time. Treating each visit as though it came from a different participant can misstate uncertainty. The registry record does not identify a longitudinal model, a covariance structure, or another method for handling repeated measurements. It is therefore not possible to determine how dependence among each participant's measurements was handled.

What would a confidence interval add?

In general, a confidence interval gives a range of values compatible with the data and the statistical model under repeated sampling. Its width conveys precision: a narrower interval indicates a more precise estimate under that model, while a wider interval indicates greater uncertainty. The interval's interpretation depends on the estimand, analysis population, model, and assumptions. A confidence interval is not a guarantee that the true value lies within the particular calculated interval. No confidence interval for the primary outcome is reported in the registry record.

A p-value, if reported, would address how compatible the observed data are with a specified null hypothesis under the test's assumptions. It would not measure the size or importance of an effect, and it would not establish causation. The registry lists 0 analyses, so no p-value or hypothesis test result is reported. The absence of a test result should not be interpreted as evidence that there is no change; it means the record does not report an analysis result.

What do the planning assumptions mean?

General power calculations estimate the sample size needed to detect an effect under specified assumptions. The registry's planning description refers to a two-sided significance level of 0.05, equal allocation between two arms, a normal approximation, and an effect defined as a stated fraction of an observed effect. It describes per-arm participant counts for most outcomes and a total event count for time-to-event outcomes. These are planning illustrations, not observed power, and they do not describe the actual single-group design, which has no two-arm allocation. The registry record does not report the numerical planning estimates or the trial's own sample-size justification. No planning illustration can substitute for an analysis of the enrolled participants.

General power calculations also rely on assumptions about variability, the target effect, and the analysis. If those assumptions do not match the eventual data or design, the planning estimate may not describe the study's actual precision. A completed study's uncertainty is better conveyed by its observed estimate and confidence interval, alongside the analysis method and number of participants included. None of those primary-outcome results is reported in the registry record. Sample-size planning should not be read as a finding about whether the trial had adequate power after completion.

Why does the single-group design matter?

General interpretation of a single-group study focuses on within-group observations and feasibility, not a controlled causal contrast. A change in A1C after treatment can be described, but attributing that change to insulin and monitoring alone requires assumptions that cannot be checked against a concurrent comparison group in this design. Because allocation is NA and the model is single group, the record does not describe randomized evidence against usual care or another intervention. The registry also does not report whether other anti-hyperglycemic agents changed during follow-up.

For these reasons, the most useful statistical information would include clearly defined follow-up contrasts, visit-specific counts, means and standard deviations, uncertainty intervals, and a transparent account of missing measurements and the analysis population. The registry record does not report these details. The endpoint schedule and summary measures are specified, but the actual statistical evidence needed to quantify change and its precision is absent.

10. Multiplicity, Missing Data and Analysis Populations

The registry lists 6 outcome measures, including repeated A1C assessment and several secondary outcomes related to glucose targets, low glucose values, diabetes distress, and time in range. Testing or estimating many outcomes can raise multiplicity concerns: in general, when multiple hypotheses are examined, the chance of at least one apparently notable result can increase. An analysis plan may address this by identifying a primary outcome, prioritizing outcomes, or adjusting inference. The registry record does not report a multiplicity strategy, hierarchy of tests, or adjustment method. No analyses are reported, so the record does not show how multiplicity was handled in practice.

Missing data are also important for repeated measurements. The primary outcome description says that two patients did not get “baselin”—the registry wording is incomplete at that point. The reason, the measurement intended, and whether those participants contributed to later analyses are not reported in the registry record. Visit-specific participant counts, missingness by follow-up time, and any imputation or other missing-data method are also not reported. General statistical context: if the participants with observed measurements differ systematically from those without them, the analyzed results may not represent the full enrolled group.

The registry does not specify an analysis population, such as all enrolled participants or only those with particular measurements. It also does not report exclusions, adherence, protocol deviations, or the number analyzed for each outcome. Enrollment of 10 is not necessarily the number contributing to every endpoint or visit. Without analysis populations and missing-data details, precision and representativeness cannot be judged. These omissions limit interpretation independently of whether an estimated effect is large or small.

11. Safety Results

The registry reports serious adverse events as affected participants divided by participants at risk.

Deaths

Other (non-serious) adverse events

Participants with at least one non-serious event at or above the registry's 0% reporting threshold.

Most frequent non-serious adverse event terms

The safety record lists 10 participants at risk for serious adverse events and 0 affected, with 0 deaths. For other adverse events, 10 participants were at risk and 7 were affected. These are participant counts in the registry's categories; they are not a description of the number of distinct event episodes. No serious adverse-event terms are listed.

The counts do not identify the nature, timing, duration, or severity of the other adverse events. They also do not establish whether an event was judged related to the intervention. The registry record does not report additional event-level details or a comparative safety group. Because this was a single-group study, there is no separate control-arm rate for comparison.

General interpretation: a count of zero observed serious adverse events in a small study does not prove that a serious event is impossible or that risk is absent. It describes what was recorded among the participants at risk in this study. The adverse-event figures should be read alongside the limited enrollment, the absence of event details, and the lack of a control group, rather than as a complete estimate of safety.

12. What the Result Does, and Does Not, Mean

The registry record describes a feasibility pilot of early insulin therapy guided by continuous glucose monitoring among people with newly diagnosed type 2 diabetes. It identifies glargine and lispro as the insulin drugs and Dexcom G6 as the monitoring device. The intervention was intended to last up to 4 weeks, with follow-up A1C measurement at 3-month intervals up to 12 months. The stated purpose includes exploring diabetes remission.

That description explains the clinical question and measurement plan, but it does not report the primary outcome results. There are no reported A1C means, changes, standard deviations, confidence intervals, or p-values. The record therefore does not show how A1C changed, how variable the measurements were, or how precisely any change was estimated. It also does not report the number of participants who achieved A1C of <6.5% or the number achieving euglycemic glucose targets.

The design is single group and has no separate comparator. Even if a before-and-after change were reported, it would describe change over time in the participants rather than a randomized contrast. General statistical context: without a control group, it is difficult to distinguish intervention-associated change from other changes occurring during follow-up. The record does not establish that insulin therapy caused any particular outcome.

The reported safety counts include 0 serious adverse events, 7 participants affected by other adverse events, and 0 deaths among 10 participants at risk in each category. Those figures do not include enough detail to characterize the other events or compare risk with another group. The small enrollment and absence of analysis results limit what can be inferred about both outcomes and safety.

Accordingly, the record supports describing the study's design, intervention, outcome schedule, and reported adverse-event counts. It does not support a conclusion about whether the intervention achieved remission, the magnitude or durability of A1C change, or comparative benefit or harm. Those conclusions would require reported outcome analyses and fuller information about the participants included at each visit.

13. Why This Trial Matters Statistically

This study is statistically notable as a single-group feasibility pilot that pairs a brief, monitored insulin intervention with A1C follow-up extending to 12 months. The intervention is described as basal glargine and bolus lispro, with titration informed by continuous glucose monitoring. Its stated purpose is to explore whether early treatment can be followed by diabetes remission. This gives the registry record a clear clinical motivation, while the design places important limits on causal interpretation.

Repeated A1C measurements can be informative because they describe outcomes beyond the short intervention period. In general, however, longitudinal data need analysis methods that account for measurements from the same participants being related. The registry record gives a measurement schedule and summary-statistic plan, but no analysis method or results. It also notes that two patients did not get “baselin”—an incomplete phrase—so the number contributing to comparisons may not match the full enrollment. The record does not provide visit-specific counts or explain the missing measurement.

The study also illustrates the difference between an outcome's stated purpose and its reported evidence. Remission appears in the intervention rationale, while the primary outcome is change in A1C and secondary outcomes include a threshold-based A1C measure. Without results or an operational definition of remission, these aims cannot be evaluated statistically from the registry record.

Finally, planning calculations and completed-study results serve different purposes. The registry describes general planning assumptions, but those illustrations do not provide observed power or replace estimates and uncertainty from the completed study. The record reports no analysis results. For readers, the main statistical lesson is to distinguish a useful feasibility question from evidence of a treatment effect, and to distinguish a planned measurement schedule from an analyzed outcome.

14. Limitations

• The posted summary statistics are the only data these results rest on; patient-level data, full protocols and statistical analysis plans are not available.
• Recalculated results are simple, unadjusted calculations from posted summaries. They do not replace the sponsor's prespecified analysis.

The registry record has several limitations for interpreting the study's outcomes. Most importantly, it reports no analysis results despite listing the study as completed and giving enrollment of 10. No primary-outcome estimates, variability measures, confidence intervals, or p-values are reported. Thus, neither the size nor precision of A1C change can be assessed from the record.

The design is single group, with no separate comparator and allocation listed as NA. This means that changes over time cannot be contrasted with a concurrent control group. Masking is listed as NONE. The registry does not report further details about outcome assessment or efforts to limit bias.

The primary outcome description contains an incomplete statement that two patients did not get “baselin”. The record does not complete the phrase, explain the reason, or state how this affected each analysis. It does not report participant counts by visit, the analysis population, missing-data methods, or exclusions. Those omissions matter for interpreting repeated measurements and determining how much of the enrolled group informs an estimate.

Other limitations include the absence of a reported statistical analysis plan, the absence of a reported multiplicity strategy across 6 outcome measures, and limited safety-event detail. The record does not define remission operationally, report the number meeting the A1C threshold, or report the result for the other secondary outcomes. It also does not provide enough information to assess changes in other anti-hyperglycemic agents, adherence, or protocol deviations. These details are not reported in the registry record and should not be inferred.

15. Related Tutorials

16. Related Statistical Calculators

17. Sources

• ClinicalTrials.gov: Remission Through Early Monitored Insulin Therapy - Duration Month — NCT03670641.
• Registry record last updated 2021-10-12; status last verified 2021-09.
• Results first posted 2021-10-12.
• Data retrieved from ClinicalTrials.gov on 2026-11-09.
• Group sizes, means, event counts and sponsor-reported p-values are reproduced as posted. Effect estimates, confidence intervals and p-values not attributed to the sponsor are independently calculated from the posted summary statistics.

18. Record Summary

NCT03670641 is a completed Phase 4, single-group feasibility pilot with enrollment of 10. It studied early basal glargine and bolus lispro therapy, with titration guided by Dexcom G6 continuous glucose monitoring for up to 4 weeks in people with newly diagnosed type 2 diabetes who had never used insulin. The primary outcome concerns baseline A1C and measurements at 3-month intervals up to 12 months.

The registry lists 6 outcome measures and 0 analyses. It reports no primary or secondary outcome estimates. Safety counts include 0 serious adverse events, 7 participants affected by other adverse events, and 0 deaths among 10 participants at risk in each category. The record does not report a control group, analysis results, or key details about missing data and analysis populations. Its design and aims are described, but treatment effects and their precision cannot be assessed from the reported results.